Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 321

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 321
---
   |     |               | 1,601,255 |   |     |                    |  6,819,564 |   |
| Cash, restricted cash and cash equivalents                      
 at end of period                                                |     | $             |   3,380,204 |   |     | $             |   963,855 |   |     | $                  |  2,562,025 |   |
| Supplemental cash flow information:                             |     |               |             |   |     |               |           |   |     |                    |            |   |
| Cash and cash equivalents                                       |     | $             |   3,305,448 |   |     | $             |   884,099 |   |     | $                  |  2,482,269 |   |
| Restricted cash                                                 |     |               |      79,756 |   |     |               |    79,756 |   |     |                    |     79,756 |   |
| Cash, restricted cash and cash equivalents                      |     | $             |   3,380,204 |   |     | $             |   963,855 |   |     | $                  |  2,562,025 |   |
| Non-cash financing activities:                                  |     |               |             |   |     |               |           |   |     |                    |            |   |
| Issuance of common shares to Keystone Capital                   
 LLC for equity line of credit                                   |     | $             |     500,000 |   |     | $             |         - |   |     | $                  |          - |   |
| Issuance of common shares to Arena Investors                    
 LP for equity line of credit                                    |     | $             |     500,000 |   |     | $             |         - |   |     | $                  |          - |   |

<div align='center'>See accompanying notes to
the condensed consolidated financial statements.

F-6

CERO THERAPEUTICS HOLDINGS, INC.
Notes to Condensed CONSOLIDATED Financial Statements</div>

NOTE 1 – NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Nature of Operations – CERo Therapeutics
Holdings, Inc. F/K/A Phoenix Biotech Acquisition Corp. (NASDAQ: PBAX, “PBAX”) was incorporated in Delaware on June 8, 2021.
PBAX was formed